This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

15 Biotech Stock Predictions for 2011

Editor's Note: This column originally published on Dec. 15 predicted European regulatory approval of InterMune's lung drug as the company announced today. Shares of the stock more than doubled on today's news.

BOSTON ( TheStreet) -- I'm pleased to present 15 predictions for the biotech and drug sectors in 2011.

Why 15 predictions in 2011? Why not?

Some of these prognostications are serious, others not so. Almost all would be big surprises were they to come true.

1. Cell Therapeutics (CTIC - Get Report) will increase its share count to 2 billion, followed by a 60:1 reverse stock split. Pixantrone still isn't approved.

2. At least one leading U.S. academic medical center will bar its doctors from consulting with Wall Street investors. Soon after, one or more health care-focused expert networks will shutter operations.

3. Dendreon (DNDN) will experience a temporary disruption in Provenge sales due to a problem at one of its manufacturing plants.

4. By the end of the year, one or more of these companies will be gobbled up in an M&A deal: Amarin (AMRN), Seattle Genetics (SGEN - Get Report), Human Genome Sciences (HGSI), Pharmasset (VRUS), Onyx Pharmaceuticals (ONXX), Biomarin Pharmaceuticals (BMRN).

5. Arena Pharmaceuticals (ARNA - Get Report) will end 2011 still trying to convince FDA to approve its weight-loss drug lorcaserin.

6. One of the large-cap biotech companies will begin paying a dividend.

7. Sequenom's (SQNM) attempt to commercially launch a fetal DNA test for Down's syndrome will be stopped by FDA, which decides to enact stronger regulatory control over all genetic tests.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
ITMN $73.89 -0.03%
CTIC $1.74 0.00%
ARNA $4.13 0.00%
DSCO $1.11 0.00%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs